Compare MED & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MED | MOLN |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 144.0M |
| IPO Year | 1996 | 2021 |
| Metric | MED | MOLN |
|---|---|---|
| Price | $12.52 | $4.00 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $8.38 |
| AVG Volume (30 Days) | ★ 191.1K | 1.8K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $934,842,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $3.41 |
| 52 Week High | $15.37 | $5.36 |
| Indicator | MED | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.59 | 40.95 |
| Support Level | $9.91 | $3.94 |
| Resistance Level | $14.41 | $4.54 |
| Average True Range (ATR) | 0.63 | 0.08 |
| MACD | 0.12 | -0.03 |
| Stochastic Oscillator | 75.06 | 15.25 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.